Biodiversity in Medical Research: How Species Diversity Refines Analyses — Cost, Top Hospitals & Success Rates | MyMedicPlus

The role of species diversity in biomedical research represents a foundational principle that significantly impacts the quality, generalisability, and clinical applicability of scientific findings. Animal models have been central to preclinical medical research for over a century — enabling the study of disease mechanisms, drug pharmacokinetics, surgical technique development, and toxicology before human clinical trials. The choice of animal model is one of the most critical methodological decisions in translational medicine, directly determining whether laboratory findings can be validly extrapolated to human disease and treatment.

When research is conducted using diverse species — rather than relying exclusively on inbred mouse strains or a single model organism — several important analytical advantages emerge. Different species exhibit varying metabolic pathways, immune system configurations, organ physiology, and genetic polymorphisms that collectively provide a more complete picture of how a drug, surgical technique, or biological process behaves across biological variability. Findings that replicate across multiple species provide substantially stronger evidence of a truly conserved mechanism that is likely to apply to humans.

The translational gap between animal research and human clinical outcomes has been a major challenge in modern medicine — historically, approximately 90% of drugs that succeed in animal models fail in human clinical trials. Incorporating species diversity into preclinical research programmes, together with in vitro human cell models and computational modelling, is a key strategy for improving translational success rates and reducing the rate of costly late-stage clinical trial failures.

Species diversity in research has contributed to major advances across virtually all medical specialties. In cardiovascular medicine, pig models (Sus scrofa) are used to study coronary artery disease and myocardial infarction because porcine coronary anatomy and left ventricular physiology closely mirror humans — findings from pig cardiac research have directly informed the development of stenting techniques, cardiac resynchronisation therapy, and transcatheter valve replacement. In neuroscience, non-human primate models (macaque monkeys) have been essential to understanding motor cortex organisation, enabling the development of deep brain stimulation for Parkinson's disease.

For infectious disease research, ferret models are essential for influenza biology because ferrets are susceptible to human influenza strains and exhibit similar respiratory symptoms. Zebrafish models have transformed developmental biology research due to transparent embryos, rapid development, and genetic tractability — informing our understanding of organ development relevant to congenital conditions. In cancer biology, multiple rodent species and humanised mouse models (engrafted with human immune cells and tumours) provide insights into tumour microenvironment interactions and immunotherapy efficacy. Comparative genomics — studying the same genes across diverse species — has identified conserved genetic pathways underlying diseases including diabetes, obesity, ageing, and neurodegenerative disorders that have led to new therapeutic targets.

Patients directly benefit from species diversity in research through the development of better, safer, and more effective treatments that have been thoroughly validated across multiple biological systems before reaching clinical trials. In the context of clinical treatments, patients participating in early phase clinical trials benefit from the higher quality of safety and efficacy data provided by multi-species preclinical programmes. Veterinary medical advances also emerge from species diversity research — treatments developed in one species context often inform care in another, creating parallel benefits for animal and human health.

For researchers and healthcare institutions, prioritising species diversity in research design is both a scientific and ethical imperative. The 3Rs framework — Replacement (using non-animal methods where possible), Reduction (using the minimum number of animals), and Refinement (minimising suffering) — guides ethical animal research. Species selection should be scientifically justified based on the most relevant anatomical, physiological, and genetic homology to the human condition being studied. Regulatory agencies including the FDA and EMA require multi-species toxicology data before approving investigational new drug (IND) applications, reflecting the regulatory consensus that single-species data is insufficient for human safety assessment.

Multi-species preclinical research programmes can be structured in several ways depending on the research question. For small molecule drug development, the standard approach involves in vitro toxicology screening, followed by rodent (rat and mouse) efficacy studies, followed by non-rodent large animal safety studies (dog, pig, or non-human primate) to satisfy regulatory requirements. The specific species are chosen based on closest metabolic pathway similarity to humans for the drug class being studied.

For medical device development — particularly cardiovascular implants, orthopaedic implants, and neural interfaces — large animal models (ovine, porcine, or canine) are used because their organ sizes, tissue mechanics, and physiological parameters most closely match adult humans. Comparative genomic approaches leverage publicly available multi-species genome databases (NCBI, Ensembl) to identify conserved gene function across species, guiding drug target selection. Organoid technology — growing miniature human organs from patient-derived stem cells — represents a complementary approach that partially replaces animal models by providing human-specific biological data, particularly for liver toxicity, intestinal pharmacokinetics, and brain disease modelling. Incorporating findings from diverse species allows researchers to validate whether biological mechanisms are evolutionarily conserved across taxa, increasing confidence in translational relevance to human physiology. Statistical meta-analytic approaches that weight species-specific data by phylogenetic relatedness to humans are increasingly used in systematic reviews to produce more accurate effect size estimates for clinical translation.

The primary benefit of multi-species research design is improved translational validity — findings that hold true across multiple species are substantially more likely to translate into effective human treatments. The incorporation of species diversity into the preclinical development of checkpoint inhibitor immunotherapy drugs (including nivolumab and pembrolizumab) — tested across mouse, primate, and in vitro human models — contributed to the successful translation of these transformative cancer treatments. Historical failures, such as the thalidomide tragedy, occurred partly because single-species rodent safety testing failed to identify teratogenicity that was subsequently demonstrated in rabbit models.

Beyond drug development, multi-species comparative biology has yielded fundamental insights that have directly improved patient outcomes: the discovery that naked mole rats do not develop cancer despite their long lifespans has opened new avenues in oncology research; studying the extreme cardiovascular adaptations of diving mammals has informed hypoxia tolerance research relevant to cardiac surgery and stroke treatment; and comparative studies of ageing across diverse species from yeast to primates have identified conserved longevity pathways (mTOR, sirtuins) that are now therapeutic targets in human ageing research.

The limitations of species-based research must be recognised to avoid over-interpretation of animal data. No animal model perfectly replicates human disease — differences in genetics, immune function, microbiome composition, diet, and lifespan mean that findings in any single species must be interpreted with appropriate caution. The most cited example is the repeated failure of Alzheimer's disease drug candidates that performed brilliantly in amyloid precursor protein (APP) transgenic mice but failed comprehensively in human clinical trials.

The cost and ethical burden of multi-species research is substantial. Large animal studies and non-human primate research are expensive, logistically complex, and subject to strict regulatory and ethical oversight. The requirement for multi-species data can delay drug development timelines and increase costs — ultimately reflected in drug prices. Animal welfare concerns are paramount, and the scientific community continues to develop and validate in vitro, computational, and organoid-based alternatives that can reduce reliance on animal models while maintaining or improving translational quality. Regulators and research funders increasingly support 3Rs-compliant research designs.

From the perspective of translational medicine, the 'follow-up' to multi-species preclinical research is the clinical trial programme. Regulatory requirements dictate that results from multi-species preclinical safety and efficacy studies are submitted to the FDA, EMA, or CDSCO before authorisation to proceed with Phase I human trials. Post-market surveillance of approved treatments continues to generate comparative data that refines our understanding of treatment effects across diverse human populations — paralleling the goal of species diversity in preclinical research.

For researchers, the ongoing development of standardised multi-species research frameworks — including the FDA's guidance on species selection for specific drug classes, and the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for transparent reporting of animal study methodologies — ensures that research quality and comparability continue to improve. Journals and funders increasingly mandate pre-registration of animal studies and full reporting of negative results, addressing the publication bias that has historically distorted the apparent predictive value of preclinical data.

Multi-species preclinical research represents a significant component of overall drug and device development costs. A typical IND-enabling preclinical safety programme including rodent and non-rodent species costs USD 3-8 million and takes 18-36 months. Non-human primate studies are the most expensive component — a single primate study with 20 animals costs USD 500,000-2,000,000. These costs are ultimately reflected in the price of approved treatments, contributing to the high cost of novel medications in markets where development costs are borne entirely by the private sector.

Publicly funded research institutions and academic medical centres in India, China, South Korea, and Brazil have become increasingly significant contributors to multi-species preclinical research, providing high-quality contract research organisation (CRO) services at significantly lower cost than Western institutions. Indian CROs certified by the OECD Good Laboratory Practice (GLP) programme conduct multi-species toxicology studies at 40-60% lower cost than US or European equivalents, contributing to more cost-efficient drug development that may ultimately support wider access to new treatments globally. The development of international harmonised standards (ICH S-series guidelines) ensures that multi-species data generated in any country meets the requirements of all major regulatory authorities.

The scientific community is actively developing alternatives to multi-species animal research that improve both ethical profile and translational validity. Organs-on-a-chip microfluidic devices recreate the cellular architecture and fluid dynamics of specific organs (lung, gut, liver, kidney) using human cells, providing human-relevant pharmacokinetic and toxicology data that may exceed the predictive value of animal studies for certain drug classes. Human stem cell-derived organoids — three-dimensional self-organising structures recapitulating the architecture of specific organs — are validated models for intestinal, hepatic, cardiac, and neural disease.

Computational modelling and artificial intelligence-based QSAR (quantitative structure-activity relationship) models predict drug toxicity and efficacy from molecular structure without any biological testing, enabling rapid screening of candidate compounds before any animal or human testing. Human volunteer microdosing studies under Phase 0 clinical trial regulations allow the pharmacokinetics of drug candidates to be measured directly in humans at sub-therapeutic doses, providing human-specific data earlier in development. These approaches are complements to — rather than complete replacements for — multi-species animal research for the foreseeable future, and are most powerful when integrated into a hierarchical research strategy guided by the 3Rs principle.